BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Precision Therapeutics, Inc. 

2516 Jane Street

Pittsburgh  Pennsylvania  15203  U.S.A.
Phone: 1-866-CHEMOFX (1-866-243-6639) Fax: 1-866-243-2424


SEARCH JOBS




Industry
Pharmaceutical






 Company News
Precision Therapeutics, Inc. Release: Data Demonstrating The Ability Of Chemofx® To Identify Platinum-Resistant Primary Ovarian Cancer Patients Prior To Treatment Published ByThe American Journal Of Obstetrics And Gynecology 2/24/2014 8:23:29 AM    More...
Precision Therapeutics, Inc. Uses Automated Method To Extract RNA For Use In The GeneFx® Colon Signature 12/16/2013 8:21:39 AM    More...
Precision Therapeutics, Inc. Presents Clinical Data Showing the ChemoFx® Drug Response Test Has Predictive Value in Recurrent Epithelial Ovarian Cancer 11/5/2013 10:14:37 AM    More...
Precision Therapeutics, Inc. Presents Clinical Data Showing the ChemoFx® Drug Response Test Has Predictive Value in Recurrent Epithelial Ovarian Cancer 11/5/2013 7:38:33 AM    More...
Precision Therapeutics, Inc. Announces Unparalleled Results That Show Recurrent Ovarian Cancer Patients Live 65% Longer in Breakthrough Prospective Clinical Trial 8/19/2013 9:26:50 AM    More...
Precision Therapeutics, Inc. Release: ChemoFx® Chemoresponse Assay Identifies Platinum-Resistance in Primary Ovarian Cancer Patients 7/8/2013 10:15:17 AM    More...
Precision Therapeutics, Inc. to Present Clinical Data Showing Significant Association between ChemoFx® Results and Improved Outcomes in Recurrent Ovarian Cancer at the 2013 European Cancer Congress 6/20/2013 7:02:18 AM    More...
Precision Therapeutics, Inc. Presents Clinical Data Demonstrating Prediction for Platinum Resistance to First-Line Chemotherapy in Primary Ovarian Cancer at WAGO 5/9/2013 10:50:04 AM    More...
Precision Therapeutics, Inc. Presents Clinical Data Demonstrating Prediction for Platinum Resistance to First-Line Chemotherapy in Primary Ovarian Cancer at WAGO 5/9/2013 8:16:33 AM    More...
Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian to be Presented by Precision Therapeutics, Inc. at WAGO Annual Meeting 5/6/2013 10:10:18 AM    More...
12345